Nuvalent (NUVL) Competitors $84.86 +1.48 (+1.78%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$85.44 +0.58 (+0.69%) As of 08:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NUVL vs. TEVA, GMAB, SMMT, RDY, ASND, VTRS, ROIV, QGEN, ELAN, and BBIOShould you be buying Nuvalent stock or one of its competitors? The main competitors of Nuvalent include Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Roivant Sciences (ROIV), QIAGEN (QGEN), Elanco Animal Health (ELAN), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry. Nuvalent vs. Its Competitors Teva Pharmaceutical Industries Genmab A/S Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Roivant Sciences QIAGEN Elanco Animal Health BridgeBio Pharma Teva Pharmaceutical Industries (NYSE:TEVA) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk. Which has more volatility & risk, TEVA or NUVL? Teva Pharmaceutical Industries has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Nuvalent has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Does the media refer more to TEVA or NUVL? In the previous week, Teva Pharmaceutical Industries had 16 more articles in the media than Nuvalent. MarketBeat recorded 17 mentions for Teva Pharmaceutical Industries and 1 mentions for Nuvalent. Teva Pharmaceutical Industries' average media sentiment score of 0.96 beat Nuvalent's score of 0.64 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Nuvalent 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is TEVA or NUVL more profitable? Nuvalent has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -0.95%. Teva Pharmaceutical Industries' return on equity of 46.10% beat Nuvalent's return on equity.Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries-0.95% 46.10% 7.18% Nuvalent N/A -32.58%-30.14% Which has better earnings & valuation, TEVA or NUVL? Nuvalent has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeva Pharmaceutical Industries$16.54B1.40-$1.64B-$0.16-126.38NuvalentN/AN/A-$260.76M-$4.90-17.32 Do analysts rate TEVA or NUVL? Teva Pharmaceutical Industries presently has a consensus price target of $25.57, suggesting a potential upside of 26.47%. Nuvalent has a consensus price target of $118.89, suggesting a potential upside of 40.10%. Given Nuvalent's higher possible upside, analysts plainly believe Nuvalent is more favorable than Teva Pharmaceutical Industries.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.00Nuvalent 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.91 Do institutionals and insiders hold more shares of TEVA or NUVL? 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Comparatively, 10.2% of Nuvalent shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryTeva Pharmaceutical Industries and Nuvalent tied by winning 8 of the 16 factors compared between the two stocks. Get Nuvalent News Delivered to You Automatically Sign up to receive the latest news and ratings for NUVL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NUVL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NUVL vs. The Competition Export to ExcelMetricNuvalentMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.01B$3.35B$6.09B$10.54BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-17.3221.5785.5627.61Price / SalesN/A271.42535.65201.06Price / CashN/A47.1237.9261.55Price / Book5.6610.1413.036.76Net Income-$260.76M-$52.31M$3.30B$275.88M7 Day Performance1.19%5.14%4.35%2.81%1 Month Performance7.79%14.68%9.50%9.24%1 Year Performance-16.20%30.98%85.16%35.42% Nuvalent Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NUVLNuvalent2.9495 of 5 stars$84.86+1.8%$118.89+40.1%-17.1%$6.01BN/A-17.3240Analyst ForecastTEVATeva Pharmaceutical Industries3.1669 of 5 stars$19.17+4.5%$25.14+31.2%+15.3%$21.04B$16.54B-119.8136,830Analyst ForecastAnalyst RevisionGMABGenmab A/S4.3434 of 5 stars$29.33+0.9%$40.00+36.4%+38.8%$18.65B$3.12B14.742,682Analyst ForecastHigh Trading VolumeSMMTSummit Therapeutics3.1749 of 5 stars$21.16+1.0%$31.29+47.9%+18.5%$15.56BN/A-20.95110Analyst ForecastRDYDr. Reddy's Laboratories3.282 of 5 stars$13.96-1.9%$16.95+21.5%-11.1%$11.87B$334.26B21.1427,811News CoveragePositive NewsAnalyst ForecastASNDAscendis Pharma A/S3.0302 of 5 stars$191.60-0.2%$244.36+27.5%+59.1%$11.83B$393.54M-37.131,017News CoveragePositive NewsAnalyst ForecastVTRSViatris1.678 of 5 stars$9.62+1.1%$10.40+8.1%-11.9%$11.10B$14.74B-3.3232,000Analyst ForecastROIVRoivant Sciences3.6509 of 5 stars$15.10-0.5%$19.94+32.0%+42.1%$10.36B$23.23M-21.57860Analyst ForecastInsider TradeQGENQIAGEN4.3737 of 5 stars$43.880.0%$49.69+13.2%+12.8%$9.76B$1.98B25.935,765Analyst ForecastELANElanco Animal Health2.6912 of 5 stars$19.63+0.1%$18.33-6.6%+40.6%$9.74B$4.44B22.829,000Trending NewsAnalyst UpgradeBBIOBridgeBio Pharma4.1987 of 5 stars$51.96+3.8%$63.94+23.1%+123.6%$9.57B$221.90M-12.70400Analyst Forecast Related Companies and Tools Related Companies TEVA Competitors GMAB Competitors SMMT Competitors RDY Competitors ASND Competitors VTRS Competitors ROIV Competitors QGEN Competitors ELAN Competitors BBIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NUVL) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvalent, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvalent With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
